30 Day Trial

Stryker VertaPlex HV PMMA Receives FDA Clearance to Treat Sacral Insufficiency Fractures

Share:

Stryker Interventional Spine received FDA clearance to market expanded indications of VertaPlex® HV to treat sacral insufficiency fractures, marking what is reportedly the first polymethylmethacrylate bone cement to receive 510(k) clearance for the fixation of pathological fractures of the sacral ala using sacroplasty.

The higher viscosity of VertaPlex HV may help reduce cement extravasation when treating porous sacral bone with the comorbidity of osteoporosis.

Source: Stryker